Data Exclusivity Remains A Top Issue In U.S. Trade Representative's 2011 Special 301 Report
This article was originally published in PharmAsia News
Executive Summary
The failure of U.S. trading partners to adequately protect pharmaceutical test data remains one of the top concerns of the United States Trade Representative in its 2011 Special 301 Report on intellectual property rights
You may also be interested in...
Trans-Pacific Partnership Pact Set As Test Ground For Getting Biologics Data Exclusivity At National Levels
While much of the talk on data exclusivity for biologics in the Trans-Pacific Partnership has focused on the 12-year window in U.S. law, sources said current thinking is to get the other nations to agree to approve their own standards within a set time frame and use that as a template for future free trade agreements.
Trans-Pacific Partnership Pact Set As Test Ground For Getting Biologics Data Exclusivity At National Levels
While much of the talk on data exclusivity for biologics in the Trans-Pacific Partnership has been on the 12-year window in U.S. law, sources said current thinking is to get the other nations to agree to approve their own standards within a set time frame and use it as a template for future free trade agreements.
Forced Technology Transfer Hinders Innovation In China – USTR
China still has major intellectual property enforcement problems that unfairly disadvantage U.S. IP rights holders in the country.